Temozolomide is an oral alkylating agent approved for patients with glioblastoma, and the efficacy of the drug in this disease is related to a validated predictive biomarker; the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. Here, MGMT is linked to glioblastoma.